Published in Cancer Res on July 01, 1998
Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer. Science (2008) 3.16
TGF-β: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst (2014) 2.08
TGF-beta signaling alterations and susceptibility to colorectal cancer. Hum Mol Genet (2007) 1.77
Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol (2010) 1.62
Role of transforming growth factor-beta in hematologic malignancies. Blood (2006) 1.41
Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development. Cancer Res (2009) 1.26
Constitutively decreased TGFBR1 allelic expression is a common finding in colorectal cancer and is associated with three TGFBR1 SNPs. J Exp Clin Cancer Res (2010) 1.05
No major association between TGFBR1*6A and prostate cancer. BMC Genet (2004) 0.98
Brachydactyly type B: linkage to chromosome 9q22 and evidence for genetic heterogeneity. Am J Hum Genet (1999) 0.97
Somatic acquisition of TGFBR1*6A by epithelial and stromal cells during head and neck and colon cancer development. Hum Mol Genet (2007) 0.92
Role of polymorphisms in Adamantiades-Behçet's disease. J Rheumatol (2008) 0.91
Candidate gene association studies: successes and failures. Curr Opin Genet Dev (2010) 0.89
Brachydactyly type B: clinical description, genetic mapping to chromosome 9q, and evidence for a shared ancestral mutation. Am J Hum Genet (1999) 0.88
Transforming growth factor Beta family: insight into the role of growth factors in regulation of fracture healing biology and potential clinical applications. Mediators Inflamm (2015) 0.84
Association between TGFBR1 polymorphisms and cancer risk: a meta-analysis of 35 case-control studies. PLoS One (2012) 0.82
Recent advances in breast cancer genetics. Cancer Treat Res (2008) 0.80
Debate about TGFBR1 and the susceptibility to colorectal cancer. World J Gastrointest Oncol (2012) 0.79
TGFBR1 and cancer susceptibility. Trans Am Clin Climatol Assoc (2014) 0.77
Transforming Growth Factor β Superfamily Signaling in Development of Colorectal Cancer. Gastroenterology (2016) 0.77
Transforming growth factor β signaling pathway associated gene polymorphisms may explain lower breast cancer risk in western Indian women. PLoS One (2011) 0.77
Association of a let-7 miRNA binding region of TGFBR1 with hereditary mismatch repair proficient colorectal cancer (MSS HNPCC). Carcinogenesis (2016) 0.76
Colorectal cancers in patients with the (9A/6A) polymorphism of TGFBR1 exhibit lesser inter-(simple sequence repeat) PCR genomic instability and present clinically at greater age. Mutat Res (2008) 0.75
Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci U S A (1999) 39.79
Pten is essential for embryonic development and tumour suppression. Nat Genet (1998) 13.41
Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science (1999) 13.19
Role of the INK4a locus in tumor suppression and cell mortality. Cell (1996) 11.41
Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem (1986) 10.00
Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell (1994) 9.48
Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell (1991) 9.40
Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature (1995) 9.03
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell (1998) 8.33
TGF beta signals through a heteromeric protein kinase receptor complex. Cell (1992) 8.12
Mechanism of activation of the TGF-beta receptor. Nature (1994) 8.10
Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A (1999) 7.88
Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science (2001) 7.13
Perception's shadow: long-distance synchronization of human brain activity. Nature (1999) 6.82
Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature (1996) 6.67
Essential role for oncogenic Ras in tumour maintenance. Nature (1999) 6.51
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature (2001) 6.36
Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood (2000) 6.27
Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics (1999) 6.23
Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet (2001) 5.92
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest (1999) 5.30
Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways. Nature (1996) 5.21
A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. Genes Dev (1999) 5.13
Mutations in human TBX5 [corrected] cause limb and cardiac malformation in Holt-Oram syndrome. Nat Genet (1997) 5.11
Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev (1995) 4.94
Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet (1997) 4.86
Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA (1997) 4.79
GS domain mutations that constitutively activate T beta R-I, the downstream signaling component in the TGF-beta receptor complex. EMBO J (1995) 4.63
Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature (1997) 4.41
A human Mad protein acting as a BMP-regulated transcriptional activator. Nature (1996) 4.36
Impaired Fas response and autoimmunity in Pten+/- mice. Science (1999) 4.25
Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem (2000) 4.24
Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol (2001) 4.22
Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev (1995) 4.19
Epileptic seizures can be anticipated by non-linear analysis. Nat Med (1998) 4.14
Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res (1997) 4.05
Inflammatory chemokine transport and presentation in HEV: a remote control mechanism for monocyte recruitment to lymph nodes in inflamed tissues. J Exp Med (2001) 3.96
Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science (1993) 3.89
A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature (1994) 3.87
Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. Cell (1998) 3.86
Isolation of human glucose-6-phosphate dehydrogenase (G6PD) cDNA clones: primary structure of the protein and unusual 5' non-coding region. Nucleic Acids Res (1986) 3.86
Type beta transforming growth factor is an inhibitor of myogenic differentiation. Proc Natl Acad Sci U S A (1986) 3.83
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res (2000) 3.83
Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem (1998) 3.83
Role of PML in cell growth and the retinoic acid pathway. Science (1998) 3.82
Anticipation of epileptic seizures from standard EEG recordings. Lancet (2001) 3.80
Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell (1994) 3.74
TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat Cell Biol (2001) 3.69
Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation. Cell (1990) 3.61
Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med (1995) 3.60
Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature (1999) 3.59
Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem (1992) 3.57
The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors. Cell (1987) 3.52
Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell (1993) 3.51
Betaglycan presents ligand to the TGF beta signaling receptor. Cell (1993) 3.48
Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell (1999) 3.47
Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature (1994) 3.46
Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev (1997) 3.45
The daf-4 gene encodes a bone morphogenetic protein receptor controlling C. elegans dauer larva development. Nature (1993) 3.45
Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. Genes Dev (1997) 3.33
A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proc Natl Acad Sci U S A (1994) 3.33
A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature (1997) 3.29
Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta. Science (1993) 3.28
The TGF-beta family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase. Genes Dev (1997) 3.28
Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-beta. J Biol Chem (1987) 3.25
Ubiquitin-dependent degradation of TGF-beta-activated smad2. Nat Cell Biol (1999) 3.25
BCL-6 protein is expressed in germinal-center B cells. Blood (1995) 3.18
Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature (1999) 3.16
Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev (1998) 3.16
OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP-Smad and Olf signaling pathways. Cell (2000) 3.12
Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4. Nature (1997) 3.12
Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature (1995) 3.11
A Smad transcriptional corepressor. Cell (1999) 3.07
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med (1996) 3.07
Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet (1996) 2.97
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet (1996) 2.93
A single mutation affects both N-acetylglucosaminyltransferase and glucuronosyltransferase activities in a Chinese hamster ovary cell mutant defective in heparan sulfate biosynthesis. Proc Natl Acad Sci U S A (1992) 2.92
The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev (2001) 2.87
The TGF beta receptor activation process: an inhibitor- to substrate-binding switch. Mol Cell (2001) 2.87
The TGF-beta family of growth and differentiation factors. Cell (1987) 2.86
GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell (1996) 2.86
Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature (2000) 2.84
The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet (1996) 2.82
Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol Cell Biol (1995) 2.80
BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA (1997) 2.78
BRCA-associated breast cancer in young women. J Clin Oncol (1998) 2.78
Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell (1992) 2.77
SMADs: mediators and regulators of TGF-beta signaling. Curr Opin Genet Dev (1998) 2.76
A randomized trial on root caries prevention in elders. J Dent Res (2010) 2.74
Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell (1991) 2.73
Genetic alterations in bladder cancer. Lancet (1993) 2.73
Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood (2001) 2.73
Ku70 is required for DNA repair but not for T cell antigen receptor gene recombination In vivo. J Exp Med (1997) 2.71